Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dectrekumab

Drug Profile

Dectrekumab

Alternative Names: Anti-IL-13 monoclonal antibody - Novartis; Anti-Interleukin-13 monoclonal antibody - Novartis; QAX-576

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Idiopathic pulmonary fibrosis; Keloids; Oesophagitis; Rectal fistula; Seasonal allergic rhinitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 27 Jan 2017 Discontinued - Phase-II for Asthma in Czech Republic, Argentina, Russia, Poland, Germany, Belgium (IV) (Novartis 20-F filed in 2017)
  • 27 Jan 2017 Discontinued - Phase-II for Idiopathic pulmonary fibrosis in United Kingdom, USA (IV) (Novartis 20-F filed in 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top